Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function
Stopped The pivotal study failed to meet the primary endpoint. Without a successful readout of the pivotal study, there was no longer a purpose for the supportive BORA-1A-C302 study.
Conditions
- Obstructive Pulmonary Function
- Restrictive Pulmonary Function
Interventions
- DRUG: single dose (100 mg) of ASA
- DRUG: single dose (162 mg) of non-enteric-coated chewable aspirin tablets
Sponsor
Vectura, Inc.
Collaborators